Our Pricing

The Science Behind Does Mounjaro Burn Fat

Published on: June 03, 2026

Understanding does mounjaro burn fat uk requires examining the dual-action mechanism of tirzepatide at a cellular level. Mounjaro doesn't directly 'burn' fat like a thermogenic supplement, but rather triggers hormonal pathways that reduce appetite, slow gastric emptying, and shift your body's energy balance toward fat oxidation—resulting in significant reductions in adipose tissue documented across multiple clinical trials.

How Does Mounjaro Work to Reduce Body Fat?

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA in the UK [1]. Rather than directly metabolising fat cells, tirzepatide works by mimicking two naturally occurring incretin hormones that regulate appetite, insulin secretion, and energy expenditure. When you inject Mounjaro subcutaneously once weekly, it activates receptors in the pancreas, gut, and brain that collectively create a sustained caloric deficit—the fundamental requirement for fat loss.

In the landmark SURMOUNT-1 trial involving 2,539 adults with obesity, participants receiving the 15mg maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks [1]. Body composition analysis revealed that the majority of this weight loss came from adipose tissue rather than lean muscle mass, with participants losing approximately 5.5kg of visceral fat—the metabolically harmful fat surrounding internal organs. This preferential fat reduction occurs because Mounjaro's appetite suppression and improved insulin sensitivity allow your body to access stored triglycerides for energy whilst preserving protein-rich tissues.

The dual-receptor mechanism distinguishes Mounjaro from single-pathway GLP-1 medications. GIP activation enhances insulin secretion in a glucose-dependent manner and may also influence fat metabolism directly through receptors in adipose tissue [2]. Meanwhile, GLP-1 receptor activation slows gastric emptying, reduces glucagon secretion, and sends satiety signals to the hypothalamus. Together, these pathways create a more pronounced metabolic shift than either hormone alone, explaining why clinical trials consistently show greater fat mass reduction with tirzepatide compared to semaglutide-based alternatives [3].

The Hormonal Pathways Behind Fat Reduction

To understand whether Mounjaro truly 'burns fat', we need to examine what happens at a hormonal level after injection. Within 30 minutes of administration, tirzepatide begins binding to GIP and GLP-1 receptors throughout your body. In the pancreatic beta cells, this binding stimulates insulin release only when blood glucose is elevated—a safety mechanism that prevents dangerous hypoglycaemia. Simultaneously, GLP-1 receptor activation in the pancreatic alpha cells suppresses glucagon, the hormone that normally signals your liver to release stored glucose.

This coordinated insulin-glucagon response fundamentally changes how your body processes energy. With glucagon suppressed and insulin optimised, your liver shifts from glucose production (gluconeogenesis) to fat oxidation. Your muscles become more insulin-sensitive, efficiently clearing glucose from the bloodstream and reducing the excess that would otherwise be converted to triglycerides and stored in adipocytes. Over weeks and months, this metabolic recalibration means your body increasingly relies on stored fat for fuel rather than dietary carbohydrates.

The appetite suppression effect is equally crucial. GLP-1 receptors in the hypothalamus—particularly the arcuate nucleus and paraventricular nucleus—regulate hunger and satiety. When tirzepatide activates these receptors, you experience reduced food cravings, earlier satiation during meals, and less preoccupation with eating [4]. In SURMOUNT-1, participants reported an average 30% reduction in daily caloric intake without being prescribed a specific diet. This spontaneous calorie reduction, combined with improved fat oxidation, creates the substantial energy deficit necessary for adipose tissue loss.

Visceral Fat vs Subcutaneous Fat Loss

Not all body fat responds equally to Mounjaro treatment. Clinical imaging studies using MRI and DEXA scans show that tirzepatide preferentially reduces visceral adipose tissue—the deep abdominal fat surrounding your liver, pancreas, and intestines—more than subcutaneous fat under the skin [1]. This pattern is metabolically advantageous because visceral fat secretes inflammatory cytokines and free fatty acids directly into the portal circulation, contributing to insulin resistance, fatty liver disease, and cardiovascular risk. By targeting this harmful fat depot first, Mounjaro may deliver health benefits beyond the number on the scale, including improvements in liver enzymes, blood pressure, and lipid profiles documented in the SURPASS trials.

Clinical Evidence: What the Trials Actually Show

The SURMOUNT clinical trial programme provides the most robust evidence for Mounjaro's effects on body composition. In SURMOUNT-1, adults with a BMI of 30 or greater (or 27 with weight-related comorbidities) were randomised to receive tirzepatide 5mg, 10mg, 15mg, or placebo, all alongside lifestyle counselling [1]. At 72 weeks, the 15mg group lost an average of 20.9kg compared to 3.1kg in the placebo group—a difference of 17.8kg. Body composition analysis revealed that approximately 85% of the weight lost was fat mass, with lean mass largely preserved.

Comparisons with semaglutide-based treatments further illuminate Mounjaro's efficacy. In the SURPASS-2 head-to-head trial, participants taking tirzepatide 15mg lost 13.4kg on average versus 9.8kg with semaglutide 1mg over 40 weeks [3]. Both medications work through GLP-1 pathways, but tirzepatide's additional GIP agonism appears to enhance fat loss by approximately 35% at equivalent treatment durations. This difference becomes particularly relevant for patients who haven't achieved their goals on single-pathway medications or who have substantial amounts of weight to lose.

It's crucial to understand that these results occurred in controlled trial settings with regular medical supervision, lifestyle support, and high adherence rates. Real-world outcomes vary based on individual factors including baseline weight, dietary habits, physical activity, genetic predisposition, and medication adherence. Your UK prescriber will monitor your progress through follow-up consultations and adjust your dose as needed to optimise fat loss whilst minimising side effects.

Long-Term Fat Loss Maintenance

One critical question is whether Mounjaro's fat-reducing effects persist long-term or plateau after initial losses. Extension data from SURMOUNT-1 shows that participants who continued tirzepatide for up to 88 weeks maintained their fat loss without significant regain, provided they remained on treatment [1]. However, discontinuation studies reveal that approximately 50% of lost weight returns within 12 months of stopping the medication, as the hormonal appetite suppression wanes and metabolic rate adjusts. This suggests Mounjaro may require long-term use for sustained fat reduction, similar to how antihypertensive medications require ongoing use to control blood pressure rather than permanently 'curing' hypertension.

Does Mounjaro Burn Fat Compared to Other Weight Loss Treatments?

When UK patients ask whether Mounjaro burns fat more effectively than alternatives, the answer depends on the comparison. Against older oral medications like orlistat, which blocks approximately 30% of dietary fat absorption, tirzepatide demonstrates substantially greater fat mass reduction—typically 15-20kg versus 3-5kg over equivalent timeframes [5]. Orlistat works through a completely different mechanism in the gut rather than systemic hormonal pathways, making it less effective for patients with significant obesity but potentially suitable for those seeking modest fat loss or who cannot tolerate injectable medications.

Compared to other GLP-1 receptor agonists, Mounjaro shows a consistent advantage. Liraglutide (Saxenda), administered as a daily injection, produces average weight loss of 8-9kg over 56 weeks in the SCALE trials—approximately half the fat reduction seen with tirzepatide at higher doses [6]. Semaglutide (Wegovy) bridges this gap somewhat, with STEP trial data showing 15-17kg average weight loss, but still falls short of tirzepatide's 20-22kg reductions in head-to-head comparisons [3]. The dual GIP/GLP-1 mechanism appears to confer a genuine metabolic advantage, though individual responses vary considerably.

For patients considering Mounjaro specifically for fat loss, it's worth noting that all these medications require prescription and clinical suitability assessment. Your UK prescriber will evaluate your BMI, weight-related health conditions, previous weight loss attempts, contraindications, and personal preferences before determining the most appropriate treatment. Some patients achieve excellent results with less expensive options, whilst others require Mounjaro's enhanced efficacy to reach clinically meaningful fat reduction targets.

Optimising Fat Loss Results with Mounjaro

Whilst Mounjaro's hormonal effects create favourable conditions for fat loss, maximising results requires complementary lifestyle modifications. Clinical trials that produced the most impressive outcomes all included structured dietary counselling and physical activity recommendations alongside medication [1]. Patients who combined tirzepatide with a modest calorie deficit (approximately 500 kcal below maintenance), regular resistance training, and adequate protein intake (1.6-2.2g per kg of lean body mass) preserved more muscle tissue and lost proportionally more fat than those relying on medication alone.

The appetite suppression caused by Mounjaro can inadvertently lead to inadequate protein intake if you're not mindful of food choices. When daily calories drop dramatically—sometimes to 1,000-1,200 kcal in the first weeks of treatment—there's a risk of losing muscle alongside fat, particularly if protein comprises less than 25% of total intake. Your prescriber may recommend working with a dietitian to ensure you're consuming sufficient protein, essential fatty acids, vitamins, and minerals whilst still maintaining the caloric deficit necessary for continued fat oxidation.

Physical activity serves multiple purposes during Mounjaro treatment. Resistance training stimulates muscle protein synthesis, counteracting the catabolic effects of rapid weight loss and preserving metabolically active lean tissue. Cardiovascular exercise increases total daily energy expenditure, accelerating the rate of fat oxidation. Regular movement also improves insulin sensitivity independently of weight loss, potentially enhancing Mounjaro's metabolic effects. Most importantly, establishing sustainable exercise habits during treatment increases the likelihood of maintaining fat loss if you eventually discontinue medication.

Managing Side Effects That Impact Fat Loss Progress

Gastrointestinal side effects—particularly nausea, vomiting, and diarrhoea—affect approximately 30-50% of Mounjaro users, especially during dose escalation [1]. Whilst these symptoms typically resolve within 4-8 weeks, they can temporarily interfere with nutrition and exercise adherence. Strategies to minimise disruption include eating smaller, more frequent meals, avoiding high-fat foods that slow gastric emptying further, staying well-hydrated, and timing your injection for a day when you can rest if needed. If side effects persist or become severe, your UK prescriber can adjust your dose or recommend symptomatic treatments to keep you on track with your fat loss goals.

Getting Started with Mounjaro at Cured Pharmacy

If you're considering Mounjaro for fat reduction, the process begins with a free online consultation with a UK-registered prescriber through Cured Pharmacy. This clinical assessment takes under three minutes and evaluates your medical history, current medications, weight loss goals, and any contraindications to tirzepatide treatment. Because Mounjaro is a prescription-only medication regulated by the MHRA, it cannot be supplied without this clinical review—a safeguard that ensures the treatment is medically appropriate for your individual circumstances.

Mounjaro treatment at Cured Pharmacy starts from £124.99, with transparent pricing displayed before you begin your consultation. This includes the medication, prescriber review, and discreet delivery to your UK address. You'll receive genuine UK-licensed Mounjaro KwikPens manufactured by Eli Lilly, along with detailed instructions for subcutaneous injection technique, dose escalation schedule, and guidance on managing potential side effects. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), and the clinical team are available by phone on (+44) 116 4646009 if you have questions during your treatment journey.

Treatment typically begins with a 2.5mg once-weekly dose for the first four weeks, allowing your body to adjust to the medication whilst minimising gastrointestinal side effects. Your prescriber will then increase the dose every four weeks—progressing through 5mg, 7.5mg, 10mg, 12.5mg, and potentially up to 15mg—based on your fat loss response and tolerability. Most patients reach their maintenance dose within 20-24 weeks, at which point fat loss continues at a steady rate until you approach your goal weight. Regular follow-up consultations ensure your treatment remains safe and effective throughout this process.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Garvey, W. T. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GIP and GLP-1 receptor agonists in the treatment of type 2 diabetes and obesity. Diabetes, Obesity and Metabolism, 23(S3), 5–21. https://doi.org/10.1111/dom.14496 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., ... & Haupt, A. (2021). Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism, 106(2), 388–396. https://doi.org/10.1210/clinem/dgaa863 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & SCALE Obesity and Prediabetes NN8022-1839 Study Group. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Results from clinical trials represent average outcomes and individual responses to Mounjaro may vary. Weight loss medications are most effective when combined with lifestyle modifications including dietary changes and increased physical activity.